



**CHRISTOPH NOWAK**

*From Sweden to France*



Project: **Molecular epidemiology and insulin resistance**


Research topic: **Medecine & Health**

Swedish Institution: **Uppsala University**

French Institution: **University Claude Bernard Lyon I**

Dates of mobility: **23/03/2015 to 04/04/2015**

Program: **SFVE-A (ex-FRÖ)**



## PRESENTATION

[Christoph Nowak](#) is Chief Medical and Business Officer at [Diamyd Medical](#) and board member of [OncoZenge AB](#). Before that, he was Assistant Professor in Molecular Epidemiology at [Karolinska Institutet](#). He obtained his MD from the [University of Oxford](#) in 2013 and his PhD from [Uppsala University](#) and the [Molecular Epidemiology group](#) in 2017 (where he was at the time of the mobility). His research has been centered on diabetes-related molecular epidemiology and insulin resistance.

## ACTIVITIES IN FRANCE

Christoph Nowak started his mobility by presenting a novel diagnostic assay developed at the University of Uppsala at the [Société Francophone du Diabète](#) in Bordeaux, where he also exchanged views with a range of participants from francophone countries who gathered for a large conference. He attended the presentations of internationally renowned researchers like [Philippe Froguel](#) and [André Scheen](#). He then travelled to [University Claude Bernard Lyon I](#), where he was hosted by [Hubert Vidal](#), who Nowak invited to Uppsala for future collaboration and the [EASD congress](#) in Stockholm later that year, and where he spent a week at the laboratory on cardiovascular and metabolic diseases ([CarMeN](#)) of the National Institute of Health and Medical Research ([INSERM](#)), attached to the [Centre Hospitalier Lyon-Sud](#). He was introduced to the five [research teams](#). Whilst Nowak's lab focuses on largescale epidemiologic cohorts and the translation of findings into cell and molecular models, the teams in Lyon work primarily on basic biomedical mechanisms using in vitro and clinical case-control designs. Nowak held a seminar on his research regarding proteomic biomarkers for insulin resistance.

A number of potential collaborations were envisaged: first, on cellular interactions between obesity, inflammation, and diabetes (Dr. [Assia Eljaafari](#)); second, on weight gain, early exposure to environmental pollutant, and metabolic consequences (Dr. [Brigitte Le Magueresse](#)); and third, on microRNA profiling to identify risk markers of diabetes (Dr. [Sophie Rôme](#)).